Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Maternal death · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes symptomatic thromboembolic events ( compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
1 finding from 1 review
Weight gain · promoting short‐term growth of preterm infants
2 findings from 1 review
Length gain, cm/week (high MCT vs low MCT) · promoting short‐term growth of preterm infants
1 finding from 1 review
Growth: head circumference (cm/week) · promoting short‐term growth of preterm infants
1 finding from 1 review
Skinfold thickness gain (mm/week) (high MCT vs low MCT) · promoting short‐term growth of preterm infants
1 finding from 1 review
Gastrointestinal intolerance · promoting short‐term growth of preterm infants
1 finding from 1 review
NEC · promoting short‐term growth of preterm infants
1 finding from 1 review
Neurodevelopmental outcomes · promoting short‐term growth of preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term growth outcomes · promoting short‐term growth of preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of cases of dementia Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
It is very uncertain whether antihypertensive therapy changes number of cases of dementia Range of compared with placebo (very low certainty).
1 finding from 1 review
Change in MMSE · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Adverse effects Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review